Treatment of Tourette's Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial
The DOI matches its Crossref record.
Abstract
Anecdotal reports in Tourette's syndrome (TS) have suggested that marijuana (cannabis sativa) and delta-9-tetrahydrocannabinol (Delta(9)-THC), the major psychoactive ingredient of marijuana, reduce tics and associated behavioral disorders. We performed a randomized double-blind placebo-controlled crossover single-dose trial of Delta(9)-THC (5.0, 7.5 or 10.0 mg) in 12 adult TS patients. Tic severity was assessed using a self-rating scale (Tourette's syndrome Symptom List, TSSL) and examiner ratings (Shapiro Tourette's syndrome Severity Scale, Yale Global Tic Severity Scale, Tourette's syndrome Global Scale). Using the TSSL, patients also rated the severity of associated behavioral disorders. Clinical changes were correlated to maximum plasma levels of THC and its metabolites 11-hydroxy-Delta(9)-tetrahydrocannabinol (11-OH-THC) and 11-nor-Delta(9)-tetrahydrocannabinol-9-carboxylic acid (THC-COOH). Using the TSSL, there was a significant improvement of tics (p=0.015) and obsessive-compulsive behavior (OCB) (p = 0.041) after treatment with Delta(9)-THC compared to placebo. Examiner ratings demonstrated a significant difference for the subscore "complex motor tics" (p = 0.015) and a trend towards a significant improvement for the subscores "motor tics" (p = 0.065), "simple motor tics" (p = 0.093), and "vocal tics" (p = 0.093). No serious adverse reactions occurred. Five patients experienced mild, transient side effects. There was a significant correlation between tic improvement and maximum 11-OH-THC plasma concentration. Results obtained from this pilot study suggest that a single-dose treatment with Delta(9)-THC is effective and safe in treating tics and OCB in TS. It can be speculated that clinical effects may be caused by 11-OH-THC. A more long-term study is required to confirm these results.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Still being checked.
Cited by
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Pharmacokinetics and Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00003 · Cited by 1,511
Cannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
Aizpurua-Olaizola, O., Soydaner, U., Öztürk, E., Schibano, D., Simsir, Y., Navarro, P., Etxebarria, N., & Usobiaga, A. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00949 · Cited by 467
the ESSTS Guidelines Group, Roessner, V., Plessen, K. J., Rothenberger, A., Ludolph, A. G., Rizzo, R., Skov, L., Strand, G., Stern, J. S., Termine, C., et al. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-011-0163-7 · Cited by 461
The therapeutic potential of cannabis
Baker, D., Pryce, G., Giovannoni, G., & Thompson, A. J. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00381-8 · Cited by 343
Tourette's syndrome: from behaviour to biology
Singer, H. S. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)01012-4 · Cited by 309
The Therapeutic Potential of Cannabis and Cannabinoids
Grotenhermen, F., & Müller-Vahl, K. (2012) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2012.0495 · Cited by 307
Self-citationFraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271
Muller-Vahl, K. R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., & Emrich, H. M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0417 · Cited by 270
Self-citationPringsheim, T., Holler-Managan, Y., Okun, M. S., Jankovic, J., Piacentini, J., Cavanna, A. E., Martino, D., Müller-Vahl, K., Woods, D. W., Robinson, M., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007467 · Cited by 252
Self-citationBaron, E. P. (2018) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.13345 · Cited by 251
Cannabinoids in health and disease
Kogan, N. M., & Mechoulam, R. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.4/nkogan · Cited by 222
Baron, E. P. (2015) · Headache: The Journal of Head and Face Pain · doi:10.1111/head.12570 · Cited by 206
Roessner, V., Eichele, H., Stern, J. S., Skov, L., Rizzo, R., Debes, N. M., Nagy, P., Cavanna, A. E., Termine, C., Ganos, C., et al. (2022) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-021-01899-z · Cited by 197
Self-citationvan der Stelt, M., Fox, S. H., Hill, M., Crossman, A. R., Petrosino, S., Di Marzo, V., & Brotchie, J. M. (2005) · The FASEB Journal · doi:10.1096/fj.04-3010fje · Cited by 199
Canadian Guidelines for the Evidence-Based Treatment of Tic Disorders: Pharmacotherapy
Pringsheim, T., Doja, A., Gorman, D., McKinlay, D., Day, L., Billinghurst, L., Carroll, A., Dion, Y., Luscombe, S., Steeves, T., et al. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205700302 · Cited by 191
Gonçalves, J., Rosado, T., Soares, S., Simão, A. Y., Caramelo, D., Luís, Â., Fernández, N., Barroso, M., Gallardo, E., & Duarte, A. P. (2019) · Medicines · doi:10.3390/medicines6010031 · Cited by 189
Bilbao, A., & Spanagel, R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02459-1 · Cited by 181
European clinical guidelines for Tourette Syndrome and other tic disorders
Roessner, V., Rothenberger, A., Rickards, H., & Hoekstra, P. J. (2011) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-011-0165-5 · Cited by 171
Lim, K., See, Y. M., & Lee, J. (2017) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2017.15.4.301 · Cited by 166
Cannabinoid–Dopamine Interaction in the Pathophysiology and Treatment of CNS Disorders
Fernández‐Ruiz, J., Hernández, M., & Ramos, J. A. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00144.x · Cited by 163
Treatment strategies for tics in Tourette syndrome
Eddy, C. M., Rickards, H. E., & Cavanna, A. E. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285610390261 · Cited by 158
Medical Cannabinoids in Children and Adolescents: A Systematic Review
Wong, S. S., & Wilens, T. E. (2017) · PEDIATRICS · doi:10.1542/peds.2017-1818 · Cited by 172
Constituents of Cannabis Sativa
Rock, E. M., & Parker, L. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-57369-0_1 · Cited by 208
Pharmacological treatment of tic disorders and Tourette Syndrome
Roessner, V., Schoenefeld, K., Buse, J., Bender, S., Ehrlich, S., & Münchau, A. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.043 · Cited by 149
How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review
Hoch, E., Niemann, D., von Keller, R., Schneider, M., Friemel, C. M., Preuss, U. W., Hasan, A., & Pogarell, O. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-019-00984-4 · Cited by 131
Current Approaches and New Developments in the Pharmacological Management of Tourette Syndrome
Quezada, J., & Coffman, K. A. (2018) · CNS Drugs · doi:10.1007/s40263-017-0486-0 · Cited by 144
Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors
van Egmond, N., Straub, V. M., & van der Stelt, M. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030220-112741 · Cited by 140
The therapeutic potential of cannabinoids for movement disorders
Kluger, B. M., Triolo, P. M., Jones, W. E., & Jankovic, J. J. (2015) · Movement Disorders · doi:10.1002/mds.26142 · Cited by 138
Singer, H. S. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000752 · Cited by 138
Current Management of Tics and Tourette Syndrome: Behavioral, Pharmacologic, and Surgical Treatments
Billnitzer, A., & Jankovic, J. J. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00914-6 · Cited by 134
Cannabinoid–dopamine interactions in the physiology and physiopathology of the basal ganglia
García, C., Palomo‐Garo, C., Gómez‐Gálvez, Y., & Fernández‐Ruíz, J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13215 · Cited by 122
Müller‐Vahl, K., Prevedel, H., Theloe, K., KOLBE, H., Emrich, H. M., & Schneider, U. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300047 · Cited by 111
Self-citationKöfalvi, A. (2007) · Springer eBooks · doi:10.1007/978-0-387-74349-3 · Cited by 116
Cannabis and Its Derivatives: Review of Medical Use
Leung, L. (2011) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2011.04.100280 · Cited by 114
Is cannabis treatment for anxiety, mood, and related disorders ready for prime time?
Turna, J., Patterson, B. A., & Ameringen, M. V. (2017) · Depression and Anxiety · doi:10.1002/da.22664 · Cited by 117
The good and the bad effects of (−) trans-delta-9-tetrahydrocannabinol (Δ9-THC) on humans
Carlini, E. A. (2004) · Toxicon · doi:10.1016/j.toxicon.2004.05.009 · Cited by 108
Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice
Umathe, S. N., Manna, S. S. S., & Jain, N. S. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.04.031 · Cited by 110
Sevy, S. M., Robinson, D. G., Napolitano, B. A., Patel, R. C., Gunduz‐Bruce, H., Miller, R., McCormack, J., Lorell, B. S., & Kane, J. M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.03.037 · Cited by 109
Cannabinoids for Tourette's Syndrome
Curtis, A., Clarke, C. E., & Rickards, H. E. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006565.pub2 · Cited by 92
Pharmacological management of tics in patients with TS
Sandor, P. (2003) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(03)00060-6 · Cited by 86
On the Pharmacological Properties of Δ9‐Tetrahydrocannabinol (THC)
Costa, B. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790146 · Cited by 97
Cannabinoid Control of Motor Function at the Basal Ganglia
Fernández‐Ruíz, J., & González, S. R. (2005) · Springer eBooks · doi:10.1007/3-540-26573-2_16 · Cited by 96
Dzierżanowski, T. (2019) · Cancers · doi:10.3390/cancers11020129 · Cited by 84
Medicinal Uses of Marijuana and Cannabinoids
Grotenhermen, F., & Müller‐Vahl, K. (2016) · Critical Reviews in Plant Sciences · doi:10.1080/07352689.2016.1265360 · Cited by 88
Self-citationCannabinoids reduce symptoms of Tourette?s syndrome
Müller‐Vahl, K. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.10.1717 · Cited by 75
Self-citationFacilitation of CB1 receptor-mediated neurotransmission decreases marble burying behavior in mice
Gomes, F. V., Casarotto, P. C., Resstel, L. B. M., & Guimarães, F. S. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.11.027 · Cited by 74
Treatment-refractory Tourette Syndrome
Kious, B. M., Shahed, J. J., & Shprecher, D. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.02.003 · Cited by 71
Tourette disorder and other tic disorders
Deeb, W., Malaty, I. A., & Mathews, C. A. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64012-3.00008-3 · Cited by 73
Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome
Abi‐Jaoude, E., Chen, L., Cheung, P., Bhikram, T., & Sandor, P. (2017) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.16110310 · Cited by 71
Dronabinol, a cannabinoid agonist, reduces hair pulling in trichotillomania: a pilot study
Grant, J. E., Odlaug, B. L., Chamberlain, S. R., & Kim, S. W. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2347-8 · Cited by 68
Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12‐Week, Randomized, Controlled Study
Müller‐Vahl, K., Fremer, C., Beals, C. R., Ivkovic, J., Loft, H., & Schindler, C. (2021) · Movement Disorders · doi:10.1002/mds.28681 · Cited by 63
Self-citationTourette syndrome and other chronic tic disorders: an update on clinical management
Martino, D., & Pringsheim, T. M. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1413938 · Cited by 66
Using animal models to develop therapeutics for Tourette Syndrome
Swerdlow, N. R., & Sutherland, A. N. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.05.003 · Cited by 62
Clinical Pharmacokinetics of Cannabinoids
Grotenhermen, F. (2003) · Journal of Cannabis Therapeutics · doi:10.1300/j175v03n01_02 · Cited by 63
Berding, G., Müller-Vahl, K., Schneider, U., Gielow, P., Fitschen, J., Stuhrmann, M., Harke, H., Buchert, R., Donnerstag, F., Hofmann, M., et al. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.01.005 · Cited by 54
Self-citationThe 5 Pillars in Tourette Syndrome Deep Brain Stimulation Patient Selection: Present and Future
Martino, D., Deeb, W., Shahed, J. J., Malaty, I. A., Pringsheim, T. M., Fasano, A. A., Ganos, C., Wu, W., & Okun, M. S. (2021) · Neurology · doi:10.1212/wnl.0000000000011704 · Cited by 55
Swerdlow, N. R., Bongiovanni, M. J., Tochen, L. S., & Shoemaker, J. M. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0374-7 · Cited by 54
Milosev, L. M., Psathakis, N., Szejko, N., Jakubovski, E., & Müller‐Vahl, K. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0050 · Cited by 59
Self-citationCerebrospinal fluid endocannabinoid levels in Gilles de la Tourette syndrome
Müller‐Vahl, K., Bîndilă, L., Lutz, B., Mußhoff, F., Skripuletz, T., Baumgaertel, C., & Sühs, K. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0671-6 · Cited by 53
Self-citationKanaan, A. S., Jakubovski, E., & Müller‐Vahl, K. (2017) · Brain Sciences · doi:10.3390/brainsci7050047 · Cited by 51
Self-citationAutism Spectrum Disorder and Medical Cannabis: Review and Clinical Experience
Mostafavi, M., & Gaitanis, J. N. (2020) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2020.100833 · Cited by 61
Guo, Z., Li, X., Zhu, W., & Xie, J. (2012) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201200928 · Cited by 46
Tourette Syndrome Treatment Updates: a Review and Discussion of the Current and Upcoming Literature
Frey, J., & Malaty, I. A. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01177-8 · Cited by 55
McKee, K. A., Hmidan, A., Crocker, C. E., Lam, R. W. M., Meyer, J. H., Crockford, D. N., Trépanier, A., Aitchison, K. J., & Tibbo, P. G. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.05.044 · Cited by 47
Emerging drugs in Tourette syndrome
Silay, Y. S., & Jankovic, J. J. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.365 · Cited by 45
Scales for hyperkinetic disorders: A systematic review
Pietracupa, S., Bruno, E., Cavanna, A. E., Falla, M., Zappia, M., & Colosimo, C. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.08.1544 · Cited by 49
Tourette syndrome is not caused by mutations in the central cannabinoid receptor (CNR1) gene
Gadzicki, D., Müller‐Vahl, K., Heller, D., Ossege, S., Nöthen, M. M., Hebebrand, J., & Stuhrmann, M. (2004) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20159 · Cited by 45
Self-citationMedical Marijuana Initiatives: Are They Justified? How Successful Are They Likely to Be?
Hall, W., & Degenhardt, L. J. (2003) · CNS Drugs · doi:10.2165/00023210-200317100-00001 · Cited by 44
Tourette's syndrome: clinical features, pathophysiology, and therapeutic approaches.
Müller, N. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.2/nmueller · Cited by 52
Impact of placebo assignment in clinical trials of tic disorders
Cubo, E., González, M., Singer, H. S., Mahone, E. M., Scahill, L. D., Müller‐Vahl, K., de la Fuente‐Fernández, R., Armesto, D., & Kompoliti, K. (2013) · Movement Disorders · doi:10.1002/mds.25365 · Cited by 42
Self-citationThe pharmacology of Tourette syndrome
Thomas, R., & Cavanna, A. E. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-0979-z · Cited by 46
Prospects for the Use of Cannabinoids in Psychiatric Disorders
Graczyk, M., Łukowicz, M., & Dzierżanowski, T. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.620073 · Cited by 51
Müller, T. D., Reichwald, K., Wermter, A., Brönner, G., Nguyen, T. T., Friedel, S., Koberwitz, K., Engeli, S., Lichtner, P., Meitinger, T., et al. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.01.002 · Cited by 43
Müller‐Vahl, K., Pisarenko, A., Szejko, N., Haas, M., Fremer, C., Jakubovski, E., Musil, R., Münchau, A. M., Neuner, I., Huys, D., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115135 · Cited by 47
Self-citationEndocannabinoid analogues exacerbate marble-burying behavior in mice via TRPV1 receptor
Umathe, S. N., Manna, S. S. S., & Jain, N. S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.030 · Cited by 44
Medical marijuana in neurology
Benbadis, S. R., Sanchez‐Ramos, J., Bozorg, A. M., Giarratano, M., Kalidas, K., Katzin, L. W., Robertson, D. S., Vu, T., Smith, A., & Zesiewicz, T. A. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.985209 · Cited by 46
Roy, R., Rakshit, S., Bhowmik, T., Khan, S., Ghatak, A., & Bhar, S. (2014) · The Journal of Organic Chemistry · doi:10.1021/jo5011125 · Cited by 40
Jakubovski, E., & Müller‐Vahl, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081739 · Cited by 41
Self-citationCannabis in the Treatment of Dystonia, Dyskinesias, and Tics
Koppel, B. S. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0376-4 · Cited by 41
Pandey, S., & Dash, D. (2019) · The Neurologist · doi:10.1097/nrl.0000000000000218 · Cited by 40
Fu, Z., Pan, J., Xu, D., & Xie, J. (2014) · RSC Advances · doi:10.1039/c4ra07860h · Cited by 37
Cannabis-based medicine in treatment of patients with Gilles de la Tourette syndrome
Szejko, N., Saramak, K., Lombroso, A., & Müller-Vahl, K. (2021) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2021.0081 · Cited by 40
Self-citationBehavioral effects of the novel cannabinoid full agonist AM 411
McLaughlin, P. J., Lü, D., Winston, K. M., THAKUR, G., Swezey, L. A., Makriyannis, A., & Salamone, J. D. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.02.005 · Cited by 36
Clinical Pharmacodynamics of Cannabinoids
Grotenhermen, F. (2004) · Journal of Cannabis Therapeutics · doi:10.1300/j175v04n01_03 · Cited by 43
Nondopaminergic Neurotransmission in the Pathophysiology of Tourette Syndrome
Udvardi, P. T., Nespoli, E., Rizzo, F. R., Hengerer, B., & Ludolph, A. G. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411546-0.00004-4 · Cited by 40
The Potential of Cannabinoid-Based Treatments in Tourette Syndrome
Artukoglu, B. B., & Bloch, M. H. (2019) · CNS Drugs · doi:10.1007/s40263-019-00627-1 · Cited by 40
A Double-Blind, Randomized, Controlled Crossover Trial of Cannabis in Adults with Tourette Syndrome
Abi‐Jaoude, E., Bhikram, T., Parveen, F., Levenbach, J., Lafrenière‐Roula, M., & Sandor, P. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0091 · Cited by 38
Wilson, J., Dobson, O., Langcake, A., Mishra, P., Bryant, Z., Leung, J., Dawson, D., Graham, M., Teesson, M., Freeman, T. P., et al. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00015-5 · Cited by 48
Single center experience with medical cannabis in Gilles de la Tourette syndrome
Thaler, A., Arad, S., Schleider, L. B., Knaani, J., Taichman, T., Giladi, N., & Gurevich, T. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.10.004 · Cited by 35
Tetrahydrocannabinol and Cannabidiol in Tourette Syndrome
Mosley, P. E., Webb, L., Suraev, A. S., Hingston, L., Turnbull, T. A., Foster, K. A., Ballard, E. L., Gomes, L., Mohan, A., Sachdev, P. S., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300012 · Cited by 36
Marijuana Compounds: A Nonconventional Approach to Parkinson’s Disease Therapy
Babayeva, M., Assefa, H., Basu, P., Chumki, S. R., & Loewy, Z. G. (2016) · Parkinson s Disease · doi:10.1155/2016/1279042 · Cited by 47
Cannabis Improves Obsessive-Compulsive Disorder—Case Report and Review of the Literature
Szejko, N., Fremer, C., & Müller‐Vahl, K. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00681 · Cited by 33
Self-citationMüller‐Vahl, K., Fremer, C., Beals, C. R., Ivkovic, J., Loft, H., & Schindler, C. (2021) · Pharmacopsychiatry · doi:10.1055/a-1675-3494 · Cited by 31
Self-citationThe treatment of Tourette’s syndrome: current opinions
Müller‐Vahl, K. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.7.899 · Cited by 34
Self-citationUpdates in Medical and Surgical Therapies for Tourette Syndrome
Malaty, I. A., & Akbar, U. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0458-4 · Cited by 33
Premonitory Urge and Tic Severity, Comorbidities, and Quality of Life in Chronic Tic Disorders
Brandt, V. C., Essing, J., Jakubovski, E., & Müller‐Vahl, K. (2023) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13742 · Cited by 37
Self-citation
Metadata
- Authors
- Müller-Vahl, K., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., Daldrup, T., & Emrich, H.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Heinrich Heine University Düsseldorf (DE)
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 2002-04-12
- Volume
- 35
- Issue
- 02
- Pages
- 57-61
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W2041869734
- Cited by
- 256
- References
- 0
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 10 · 2023: 23 · 2022: 29 · 2021: 16 · 2020: 18 · 2019: 12 · 2018: 13 · 2017: 12 · 2016: 7 · 2015: 11 · 2014: 9 · 2013: 5 · 2012: 8
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacopsychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- Tourette syndrome, delta-9-tetrahydrocannabinol, cannabis, tics, obsessive-compulsive behavior, 11-hydroxy-THC, THC metabolites, single-dose therapy, vocal tics, treatment efficacy and safety
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Female, Tourette Syndrome, Humans, Male, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Dronabinol, Treatment Outcome, Cross-Over Studies, Tics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.